Profile
Hans-Ulrich Demuth was the founder of Vivoryon Therapeutics NV, which was founded in 1997, where he held the title of Chief Scientific Officer from 2009 to 2013.
He was also a Co-Managing Director at Ingenium Pharmaceuticals GmbH in 2012.
In addition, he was a Principal at Hochschule Anhalt and a Mitglied at Martin-Luther-Universität Halle-Wittenberg.
Dr. Demuth received his undergraduate degree from Martin-Luther-Universität Halle-Wittenberg.
Former positions of Hans-Ulrich Demuth
| Companies | Position | End |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Founder | 31/01/2013 |
| Hochschule Anhalt | Corporate Officer/Principal | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Chief Executive Officer | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
Training of Hans-Ulrich Demuth
| Martin-Luther-Universität Halle-Wittenberg | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Private companies | 1 |
|---|---|
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
- Stock Market
- Insiders
- Hans-Ulrich Demuth
